GILD Gilead Sciences Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 20.35 P/E
- 7.86 P/S
- 8.33 P/B
- 4.414 EPS
- 39.33% Cash ROIC
- 0.34 Cash Ratio
- 0 / 0% Dividend
- 11.84M Avg. Vol.
- 1.53B Shares
- 139.3B Market Cap.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
Motley Fool - Jul 22, 2014
Gilead hepatitis C drug Sovaldi racks up $3.5 billion in quarter - Reuters
ETF Daily News - 11 hours ago
Why Gilead Sciences (GILD) Stock Is Up Today - TheStreet.com
ETF Daily News (blog) - 7 hours ago
TheStreet.com - Jul 21, 2014
Street Register - 13 hours ago
Nature World News - Jul 24, 2014
WKRB News - 13 hours ago
Los Angeles Times - Jul 11, 2014
Trade-Ideas: Gilead (GILD) Is Today's New Lifetime High Stock - TheStreet.com
Tech News - 14 hours ago
Seeking Alpha (registration) - Jul 24, 2014